These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 32443912)

  • 1. Update on Atypicalities of Central Nervous System in Autism Spectrum Disorder.
    Shuid AN; Jayusman PA; Shuid N; Ismail J; Kamal Nor N; Naina Mohamed I
    Brain Sci; 2020 May; 10(5):. PubMed ID: 32443912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures.
    Rossignol DA; Frye RE
    Mol Psychiatry; 2012 Apr; 17(4):389-401. PubMed ID: 22143005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dietary Phytochemicals as Neurotherapeutics for Autism Spectrum Disorder: Plausible Mechanism and Evidence.
    Bhandari R; Paliwal JK; Kuhad A
    Adv Neurobiol; 2020; 24():615-646. PubMed ID: 32006377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rational use of mesenchymal stem cells in the treatment of autism spectrum disorders.
    Liu Q; Chen MX; Sun L; Wallis CU; Zhou JS; Ao LJ; Li Q; Sham PC
    World J Stem Cells; 2019 Feb; 11(2):55-72. PubMed ID: 30842805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond infection - Maternal immune activation by environmental factors, microglial development, and relevance for autism spectrum disorders.
    Bilbo SD; Block CL; Bolton JL; Hanamsagar R; Tran PK
    Exp Neurol; 2018 Jan; 299(Pt A):241-251. PubMed ID: 28698032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Abnormalities in Autism Spectrum Disorder-Could They Hold Promise for Causative Treatment?
    Gładysz D; Krzywdzińska A; Hozyasz KK
    Mol Neurobiol; 2018 Aug; 55(8):6387-6435. PubMed ID: 29307081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autism Spectrum Disorder: Signaling Pathways and Prospective Therapeutic Targets.
    Baranova J; Dragunas G; Botellho MCS; Ayub ALP; Bueno-Alves R; Alencar RR; Papaiz DD; Sogayar MC; Ulrich H; Correa RG
    Cell Mol Neurobiol; 2021 May; 41(4):619-649. PubMed ID: 32468442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions.
    Lacivita E; Perrone R; Margari L; Leopoldo M
    J Med Chem; 2017 Nov; 60(22):9114-9141. PubMed ID: 29039668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coactivation of Autonomic and Central Nervous Systems During Processing of Socially Relevant Information in Autism Spectrum Disorder: A Systematic Review.
    Karjalainen S; Aro T; Parviainen T
    Neuropsychol Rev; 2024 Mar; 34(1):214-231. PubMed ID: 36849624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence linking oxidative stress, mitochondrial dysfunction, and inflammation in the brain of individuals with autism.
    Rossignol DA; Frye RE
    Front Physiol; 2014; 5():150. PubMed ID: 24795645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The genetics of autism.
    Muhle R; Trentacoste SV; Rapin I
    Pediatrics; 2004 May; 113(5):e472-86. PubMed ID: 15121991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Innate immune dysfunction and neuroinflammation in autism spectrum disorder (ASD).
    Hughes HK; R J Moreno ; Ashwood P
    Brain Behav Immun; 2023 Feb; 108():245-254. PubMed ID: 36494048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Gut-Immune-Brain Axis in Autism Spectrum Disorders; A Focus on Amino Acids.
    van Sadelhoff JHJ; Perez Pardo P; Wu J; Garssen J; van Bergenhenegouwen J; Hogenkamp A; Hartog A; Kraneveld AD
    Front Endocrinol (Lausanne); 2019; 10():247. PubMed ID: 31057483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glutamate mediated signaling in the pathophysiology of autism spectrum disorders.
    Choudhury PR; Lahiri S; Rajamma U
    Pharmacol Biochem Behav; 2012 Feb; 100(4):841-9. PubMed ID: 21756930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroinflammation in Autism Spectrum Disorders: Role of High Mobility Group Box 1 Protein.
    Dipasquale V; Cutrupi MC; Colavita L; Manti S; Cuppari C; Salpietro C
    Int J Mol Cell Med; 2017; 6(3):148-155. PubMed ID: 29682486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuropsychopathology of Autism Spectrum Disorder: Complex Interplay of Genetic, Epigenetic, and Environmental Factors.
    Bhandari R; Paliwal JK; Kuhad A
    Adv Neurobiol; 2020; 24():97-141. PubMed ID: 32006358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innate Immune Dysfunction and Neuroinflammation in Autism Spectrum Disorder (ASD).
    Hughes HK; Moreno RJ; Ashwood P
    Focus (Am Psychiatr Publ); 2024 Apr; 22(2):229-241. PubMed ID: 38680981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-glutamatergic dysfunction as a central mechanism of the autism spectrum disorders.
    Blaylock RL; Strunecka A
    Curr Med Chem; 2009; 16(2):157-70. PubMed ID: 19149568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot study of high-dose intravenous immunoglobulin 5% for autism: Impact on autism spectrum and markers of neuroinflammation.
    Melamed IR; Heffron M; Testori A; Lipe K
    Autism Res; 2018 Mar; 11(3):421-433. PubMed ID: 29427532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune dysfunction and neuroinflammation in autism spectrum disorder.
    Bjorklund G; Saad K; Chirumbolo S; Kern JK; Geier DA; Geier MR; Urbina MA
    Acta Neurobiol Exp (Wars); 2016; 76(4):257-268. PubMed ID: 28094817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.